Clinical trials: Dyslipidemias
Primary Hypercholesterolemia, Mixed Hyperlipemia
Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage
The study is ongoing to evaluate the efficacy and safety of SHR-1209 in patients with hypercholesterolemia and hyperlipemia.
- Trial name
- NCT04849000
- Testing
- SHR-1209
- Where
- China
- Volunteers
- 709 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
LPL Deficiency
Alipogene Tiparvovec for the Treatment of LPLD Patients
The aim of the study is to provide further confirmatory evidence of clinical benefit in LPLD patients treated with alipogene tiparvovec by assessing both the "clinical response" (as defined by a range of parameters), and "the…
- Trial name
- NCT02904772
- Testing
- alipogene tiparvovec, Prednisolone, Cyclosporins
- Where
- 2 sites in United States, Canada
- Sponsor
- UniQure Biopharma B.V.
Hypertriglyceridemia
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
This is a double-blind, randomized, olive oil-controlled study to investigate the efficacy and safety of Epanova as an adjunct therapy to diet for reduction of TG levels in subjects with severe hypertriglyceridemia.
- Trial name
- EVOLVEII (NCT02009865)
- Testing
- Epanova, Olive Oil
- Where
- 40 sites in United States, Canada and 5 more
- Volunteers
- 379 people
- Sponsor
- AstraZeneca
Dyslipidemias, High Cholesterol
Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholesterolemia (HeFH) and/or ASCVD to evaluate the efficacy, safety, and tolerability of…
- Conditions
- Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia
- Trial name
- BROADWAY (NCT05142722)
- Testing
- Obicetrapib
- Where
- 181 sites in United States, China and 6 more
- Volunteers
- 2,530 people
- Sponsor
- NewAmsterdam Pharma
Hypercholesterolemia
A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level
The primary objective of the study is to assess pharmacokinetics, dynamics, safety and tolerability of CiVi007 following single and multiple subcutaneous doses in subjects, including those on statin therapy
- Trial name
- NCT03427710
- Testing
- CiVi007
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Civi Biopharma, Inc.
Lipid Metabolism, Inborn Errors, Hyperlipidemias
Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration
This study will assess what, if any, effect that ISIS 301012 (mipomersen) has on liver triglyceride content in multiple groups of subjects with varying degrees of risk for hepatic steatosis.
- Conditions
- Lipid Metabolism, Inborn Errors, Hyperlipidemias, Metabolic Diseases, Hypolipoproteinemia
- Trial name
- NCT00362180
- Testing
- mipomersen
- Where
- Netherlands
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Kastle Therapeutics, LLC
Diabetes Mellitus, Type 2
Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors
This study was conducted to demonstrate superiority of nateglinide in postprandial glucose fluctuation, dyslipidemia, and inflammatory status improvement.
- Trial name
- ENERGY (NCT00928889)
- Testing
- Nateglinide 120 mg, Acarbose 50 mg
- Where
- 6 sites in China
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolemia, Dyslipidemia
To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C716 and C716R in Healthy Adults
To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C716 and C716R in Healthy Adults
- Trial name
- NCT07655960
- Testing
- Test Drug, Reference Drug
- Where
- South Korea
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- AJU Pharm Co., Ltd.
Hypercholesterolaemia
Study of Asian Patients With Hypercholesterolaemia in the UK - Rosuvastatin 5mg Versus Atorvastatin 10mg
The purpose of this study is to compare the effectiveness and safety of rosuvastatin 5mg in lowering blood cholesterol, compared to one other medicine, atorvastatin 10mg in Asian patients in the UK.
- Trial name
- NCT00427960
- Testing
- Dietary advice, rosuvastatin, atorvastatin
- Where
- 9 sites in United Kingdom
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
K-924 Phase III Long Term Study
A Multicenter, Open-label Study to Evaluate 52 weeks long term Efficacy and Safety of K-924 in Patients with hypercholesterolemia who were treated with pitavastatin 2 mg or 4 mg.
- Trial name
- NCT04289662
- Testing
- K-924 LD, K-924 HD
- Where
- 13 sites in Japan
- Volunteers
- 110 people
- Sponsor
- Kowa Company, Ltd.
Severe Hypertriglyceridemia
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
The purpose of this study is to evaluate the efficacy and safety of K-877 in adult patients with fasting high triglyceride levels ≥500 mg/dL and <2000 mg/dL and normal renal function.
- Trial name
- NCT03001817
- Testing
- K-877, Fenofibrate
- Where
- 220 sites in United States, Belarus and 7 more
- Volunteers
- 551 people
- Sponsor
- Kowa Research Institute, Inc.
Dyslipidemias
A Study Of The Efficacy Of Atorvastatin In Lowering Cholesterol In Latin American Patients With High Cholesterol
The purpose of this study is to determine the percentage of patients who would reach a cholesterol goal after atorvastatin treatment.
- Trial name
- LA ATGOAL (NCT00645151)
- Testing
- Atorvastatin
- Where
- 33 sites in Brazil, Chile and 6 more
- Volunteers
- 512 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hyperlipidemia, Diabete Type 2
A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B
To evaluate the pharmacokinetic interaction and the safety of AD-236A and AD-236B in healthy adult volunteers
- Trial name
- NCT07730567
- Testing
- Treatment A(AD-236A), Treatment B(AD-236B), Treatment C(AD-236A+AD-236B)
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Type2 Diabetes, Dyslipidemia
Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)
The primary objective of the study is to determine whether pemafibrate administered twice daily will delay the time to first occurrence of any component of the clinical composite endpoint of: nonfatal Myocardial Infarction (MI)…
- Trial name
- PROMINENT (NCT03071692)
- Testing
- K-877
- Where
- 888 sites in United States, Argentina and 23 more
- Volunteers
- 10,544 people
- Sponsor
- Kowa Research Institute, Inc.
Dyslipidemia
A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects
The study is being conducted to evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of HRS-5632 Following a Single Subcutaneous Injection in Healthy Subjects
- Trial name
- NCT06732154
- Testing
- HRS-5632
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Severe Hypertriglyceridemia (sHTG), Hypertriglyceridemia
A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial to assess the efficacy and safety of weekly subcutaneous DR10624 injection in adult patients with severe hypertriglyceridemia (sHTG).
- Trial name
- NCT07693777
- Testing
- DR10624 Injection
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
Obesity
A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity
The purpose of this study is to compare the efficacy and safety of topiramate (96, 192, and 256mg daily) with placebo in long-term treatment of obesity.
- Trial name
- NCT00236639
- Testing
- topiramate
- Volunteers
- 1,293 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hyperlipidemias
Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels
The purpose of this study is to compare changes in cholesterol levels in patients with elevated blood cholesterol with administration of lapaquistat acetate, once daily (QD), and fenofibrate.
- Trial name
- NCT00813527
- Testing
- Lapaquistat acetate and fenofibrate, Fenofibrate
- Where
- 36 sites in United States, Canada
- Volunteers
- 213 people
- Sponsor
- Takeda
Essential Hypertension, Dyslipidemia
Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia
The objective of this clinical study is to evaluate the efficacy and safety by comparing the fimasartan/amlodipine/rosuvastatin treatment group to the fimasartan/amlodipine treatment group and the fimasartan/rosuvastatin…
- Trial name
- FIRST (NCT03156842)
- Testing
- Fimasartan/Amlodipine, Rosuvastatin, Fimasartan/Amlodipine, Fimasartan, Rosuvastatin
- Where
- South Korea
- Volunteers
- 138 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypercholesterolemia, Hypertriglyceridemia
Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED)
The purpose of this study is to assess the cholesterol lowering safety and effectiveness of two investigational drugs in patients with mixed hyperlipidemia (high cholesterol and high triglycerides).
- Trial name
- NCT00092573
- Testing
- MK0653, ezetimibe, Comparator: fenofibrate monotherapy
- Volunteers
- 576 people
- Sponsor
- Organon and Co
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.